Aflibercept
- Generic Name
- Aflibercept
- Brand Names
- Eylea, Zaltrap, Yesafili
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 862111-32-8
- Unique Ingredient Identifier
- 15C2VL427D
- Background
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15%...
- Indication
The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
...
- Associated Conditions
- Branch Retinal Vein Occlusion With Macular Edema, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Macular Edema With Central Retinal Vein Occlusions, Metastatic Colorectal Cancer (CRC), Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD), Retinopathy of Prematurity (ROP)
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
- Conditions
- Interventions
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 557
- Registration Number
- NCT04964089
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇺🇸Retina Consultants of Texas, Houston, Texas, United States
🇺🇸Medical Center Ophthalmology Associates, San Antonio, Texas, United States
Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD
- Conditions
- Interventions
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Berner Augenklinik
- Target Recruit Count
- 80
- Registration Number
- NCT04932980
- Locations
- 🇨🇭
Berner Augenklinik, Bern, Switzerland
Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Clover Biopharmaceuticals AUS Pty Ltd
- Registration Number
- NCT04919096
A Study of IBI302 in Patients With nAMD
- Conditions
- Interventions
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 231
- Registration Number
- NCT04820452
- Locations
- 🇨🇳
Innovent Biologics (Suzhou) Co,Ltd., Suzhou, Jiangsu, China
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
- Conditions
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 553
- Registration Number
- NCT04740905
- Locations
- 🇵🇱
Gabinet Okulistyczny Prof Edward Wylegala, Katowice, Poland
🇺🇸Cumberland Valley Retina PC, Hagerstown, Maryland, United States
🇦🇺The Lions Eye Institute, Nedlands, Western Australia, Australia
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
- Conditions
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 729
- Registration Number
- NCT04740931
- Locations
- 🇺🇸
Fort Lauderdale Eye Institute, Plantation, Florida, United States
🇺🇸Assoc Retinal Consultants PC, Royal Oak, Michigan, United States
🇺🇸Midwest Vision Research Foundation, Chesterfield, Missouri, United States
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Gemini Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04684394
- Locations
- 🇺🇸
Gemini Clinical Trial Site 18, Winter Haven, Florida, United States
🇺🇸Gemini Clinical Trial Site 7, Pinellas Park, Florida, United States
🇺🇸Gemini Clinical Trial Site 2, Asheville, North Carolina, United States
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 494
- Registration Number
- NCT04662944
- Locations
- 🇪🇸
Novartis Investigative Site, Leon, Spain
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
- Conditions
- Interventions
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 460
- Registration Number
- NCT04611152
- Locations
- 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸MidAtlantic Retina, Philadelphia, Pennsylvania, United States
🇺🇸Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
- Conditions
- Interventions
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 459
- Registration Number
- NCT04603937
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cole Eye Institute, Cleveland, Ohio, United States
🇫🇷CHRU Dijon Complexe Du Bocage, Dijon, Côte-d'Or, France
🇺🇸Retina Specialists of Idaho, Boise, Idaho, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.